Zevra Therapeutics, Inc. (ZVRA) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

20/25

Growth 5 Margin 5 Expansion 3 Platform 3 Financial 4

latest quarter score

Earnings Reports

20
ZVRA Q2 2026: MyClypha Drives 53% Revenue Gain as U.S. Patient Mix Broadens
August 06, 2026
21
Zephyr (ZVRA) Q1 2026: MyPlypha Reaches 50% Diagnosed U.S. NPC Share, Unlocking Rare Disease Scale
May 07, 2026
19
ZVRA Q4 2025: MyPlypha Drives 52 Annual Enrollments, Expanding Rare Disease Market Penetration
March 10, 2026
14
ZVRA Q3 2025: MyPlypha Drives 40% U.S. Share, European Launch and Diagnosis Initiatives Signal Next Growth Phase
November 06, 2025
12
Zevra (ZVRA) Q2 2025: MyPlypha Drives 26% Sequential Revenue Growth, Expands Rare Disease Reach
August 13, 2025
13
Zevra (ZVRA) Q1 2025: MyPlypha Captures One-Third of Diagnosed NPC Patients, Expanding Rare Disease Franchise
July 07, 2025
9
Zevra Therapeutics (ZVRA) Q4 2024: $150M PRV Sale and Rapid MIPLYFFA Launch Propel Rare Disease Growth
March 11, 2025

Browse all companies